Takahashi Y, Nomoto H, Yokoyama H et al (2023) Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: a multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study)
Restarting also depends on postpartum recovery
But if we had been born, let's say somebody was supposed to be normal weight 100 years ago, fast forward to right now
Medicine errors reports from the FDA also indicate that unclear medication labels, ambiguous abbreviations and complex dose calculations are also common causes of medication errors in injectable medications This risk is highlighted in the literature
and the rest were placed in a placebo group